CYTK.NASDAQCytokinetics INC

Form 4: Cytokinetics CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on August 10, 2026 for $76.76 per share.

Summary

  • Option exercise/conversion: acquired 7,500 Common Stock at $10.60 ($79,500) on August 10, 2026; holds 385,320 after (Direct).
  • Open-market sale: disposed of 7,500 Common Stock at $76.76 ($575,700) on August 10, 2026; holds 377,820 after (Direct).
  • Option exercise/conversion: disposed of 7,500 Non-Qualified Stock Option (Right to Buy) on August 10, 2026; holds 171,745 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $575,700 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Robert I Blum — Director, Officer (President & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-10Option exercise/conversionCommon Stock7,500$11$79.5K385,320
2026-08-10Open-market saleCommon Stock7,500$77$575.7K377,820
2026-08-10Option exercise/conversionNon-Qualified Stock Option (Right to Buy)7,500——171,745

Key Dates

DateDescription
2026-08-10Option exercise/conversion (7,500 shares)
2026-08-10Open-market sale (7,500 shares)
2026-08-10Option exercise/conversion (7,500 shares)

Keywords

insider transaction, Form 4, CYTK, CYTOKINETICS INC, bearish, Robert I Blum

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.